品牌 |
Leading Biology | 貨號 |
AMM02367G |
產(chǎn)品分類 |
Monoclonal Antibodies | 研究領域 |
|
產(chǎn)品概述 |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality HLA-DRA Antibody (ascites).
|
||
分子量 |
28607 Da
|
||
細胞定位 |
Antigen Cellular Localization:
Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single- pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation
|
||
宿主 |
Mouse
|
||
種屬反應性 |
Human
|
||
免疫原 |
48-75 aa
|
||
靶點 |
This HLA-DRA antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 48-75 amino acids from human HLA-DRA.
|
||
克隆號 |
302CT2.3.2
|
||
亞型 |
IgM
|
||
通用名 |
HLA-DRA1
|
||
基因ID |
|||
UniProt ID |
|||
功能 |
Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
|
||
總結 |
HLA-DRA is one of the HLA class II alpha chain paralogues.This class II molecule is a heterodimer consisting of an alpha anda beta chain, both anchored in the membrane. It plays a centralrole in the immune system by presenting peptides derived fromextracellular proteins. Class II molecules are expressed in antigenpresenting cells (APC: B lymphocytes, dendritic cells,macrophages). The alpha chain is approximately 33-35 kDa and itsgene contains 5 exons. Exon 1 encodes the leader peptide, exons 2and 3 encode the two extracellular domains, and exon 4 encodes thetransmembrane domain and the cytoplasmic tail. DRA does not havepolymorphisms in the peptide binding part and acts as the solealpha chain for DRB1, DRB3, DRB4 and DRB5.
|
||
儲存條件 |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
應用 |
WB, E
|
||
稀釋方法 |
WB~~1:500~16000
|
||
圖像 |
HLA-DRA Antibody (Cat. AMM02367G) western blot analysis in ZR-75-1 cell line lysates (35μg/lane).This demonstrates the HLA-DRA antibody detected the HLA-DRA protein (arrow). |
||
說明書 |
|||
數(shù)量 |
|
選擇 | 品牌 | 貨號 | 產(chǎn)品名稱 | 規(guī)格 | 分類 | 研究領域 | 說明書 | 數(shù)量 | 目錄價 | |
1 | Leading Biology | APG01369G | VEGF (Vascular Endothelial Growth Factor) Antibody - Without BSA and Azide | 100 μg | Monoclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
2 | Leading Biology | AMM07627G | RIN2 Antibody (monoclonal) (M01) | 100 μg | Monoclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
3 | Leading Biology | APR15980G | FGG Antibody | 100 μl | Monoclonal Antibodies |
|
¥5450.00 | 訂購 詢價 | ||
4 | Leading Biology | AMM05161G | GOB5 / CLCA1 Antibody (clone 1C4) | 50 μg | Monoclonal Antibodies |
|
¥5450.00 | 訂購 詢價 | ||
5 | Leading Biology | APR17667G | ORAI1 Antibody [3F6H5] | 0.1 mg | Monoclonal Antibodies |
|
¥6950.00 | 訂購 詢價 | ||
6 | Leading Biology | APR11118G | HIV-1 p24 Antibody [7F4] (biotin) | 0.1 mg | Monoclonal Antibodies |
|
¥6950.00 | 訂購 詢價 |
微信掃描二維碼,隨時隨地與小諾親密接觸,精彩活動,勁爆優(yōu)惠,觸手可得!